Raymond James Financial’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.7M Buy
783,065
+436,748
+126% +$6.34M ﹤0.01% 1809
2026
Q1
$3.45M Buy
346,317
+86,906
+34% +$777K ﹤0.01% 2907
2025
Q4
$2.19M Buy
259,411
+44,588
+21% +$318K ﹤0.01% 3204
2025
Q3
$1.12M Buy
214,823
+24,335
+13% +$92.8K ﹤0.01% 3609
2025
Q2
$659K Buy
190,488
+5,955
+3% +$17.7K ﹤0.01% 3833
2025
Q1
$483K Sell
184,533
-4,513
-2% -$17.7K ﹤0.01% 3957
2024
Q4
$779K Buy
+189,046
New +$1.03M ﹤0.01% 3622

Other funds holding RLAY

Raymond James Financial's RLAY Position: Q2 2026 in Review

Raymond James Financial increased its Relay Therapeutics (RLAY) stake by 126% in Q2 2026, buying an estimated $6.34M and bringing the position to 783,065 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

Raymond James Financial first reported a position in RLAY in Q4 2024 and has held it in 7 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Raymond James Financial held 783,065 shares of Relay Therapeutics worth $14.7M as of Q2 2026.
  • Raymond James Financial bought 436,748 Relay Therapeutics shares in Q2 2026, an estimated $6.34M.
  • Relay Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1809 holding.
  • Raymond James Financial first reported a position in Relay Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.